News - Lemtrada

Filter

Current filters:

Lemtrada

Popular Filters

News briefs: Eli Lilly expands insulin facility; and Sanofi criticized over Lemtrada

02-11-2012

US drug major Eli Lilly (NYSE: LLY) has announced a $140 million expansion to the company's Indianapolis…

BiotechnologyDiabetesEli LillyLemtradaNeurologicalPharmaceuticalPricingProductionSanofi

News briefs from Sanofi, Biogen/SOBI and Novartis

01-11-2012

French drug major Sanofi (Euronext: SAN) and subsidiary Genzyme have reported results from pivotal studies…

AgrippalBiogen IdecBiotechnologyFluadLemtradaNeurologicalNovartisPharmaceuticalRegulationResearchSanofiSwedish Orphan BiovitrumVaccines

FDA calls on Genzyme to re-file Lemtrada sBLA

28-08-2012

French drug major Sanofi (Euronext: SAN) revealed yesterday that its US biotech subsidiary has received…

BayerBiotechnologyGenzymeLemtradaNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Sanofi moves on Lemtrada; Novartis Indian patent case

21-08-2012

French drug major Sanofi's (Euronext: SAN) USA-based rare diseases subsidiary Genzyme is pulling leukemia…

Asia-PacificCampathEuropeGenzymeGlivecLegalLemtradaMarkets & MarketingNorth AmericaNovartisPatentsPharmaceuticalSanofi

Genzyme files multiple sclerosis drug Lemtrada with FDA and EMA

12-06-2012

French drug major Sanofi (Euronext: SAN) subsidiary Genzyme revealed this morning that it has submitted…

BayerBiotechnologyEuropeGenzymeLemtradaNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Genzyme’s MS drug Lemtrada shows significant efficacy versus Rebif

15-11-2011

US biotech firm Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN) says that the Phase…

BayerGenzymeLemtradaNeurologicalPharmaceuticalRebifResearchSanofi

Mixed Ph III results for Sanofi MS drug candidate Lemtrada; EMA to broaden review of Multaq

12-07-2011

French drug major Sanofi (Euronext: SAN) and its US biotech subsidiary Genzyme have announced mixed top-line…

AlemtuzumabBiotechnologyCardio-vascularEuropeGenzymeLemtradaMultaqPharmaceuticalRegulationResearchSanofi

Back to top